3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Dermatologic
1
CNS
1
Conditions
Glioblastoma
6
Neuroblastoma
5
Central Nervous System Neoplasms
5
Gliosarcoma
4
Medulloblastoma
3
Glioma
3
Brain Neoplasms
3
Sarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Pinealoma
2
Ependymoma
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Pyloric Stenosis, Hypertrophic
1
Osteosarcoma
1
Oligodendroglioma
1
Neurofibromatosis 1
1
Neurofibroma
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Histiocytosis, Langerhans-Cell
1
Carcinoma
1
Brainstem Glioma
1
Astrocytoma
1
Interventions
Cyclophosphamide
10
Temozolomide
8
X-Rays
7
Specimen Handling
7
Irinotecan
7
Phantoms, Imaging
6
Magnetic Resonance Spectroscopy
6
Filgrastim
6
Carboplatin
5
Biopsy
5
fludarabine
4
Nuclear Medicine Department, Hospital
4
olaparib
3
fludarabine phosphate
3
etoposide phosphate
3
dinutuximab
3
Zoledronic Acid
3
Oxaliplatin
3
Nivolumab
3
Ifosfamide
3
Granulocyte Colony-Stimulating Factor
3
Gemcitabine
3
Etoposide
3
Docetaxel
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
lorukafusp alfa
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Osteosarcoma
×
Celecoxib
×
CNS
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled